
    
      This is a single-center, single-dose, double-blind, placebo-controlled, randomized,
      crossover, abuse liability study conducted in healthy subjects who are non-dependent
      recreational opioid users. The study consists of 3 study days during which each subject will
      take one tablet of either 40mg OxyNEO®, 40mg Apo-Oxycodone CR®, or placebo. The participants
      will be assessed for both pharmacokinetic and pharmacodynamic outcomes.
    
  